Bill > S2164

This bill, the Lower Costs, More Cures Act of 2021, proposes several reforms to the Medicare program and other provisions related to drug pricing transparency and revenue. Key provisions include: - Requiring manufacturers of certain single-dose or single-use drugs under Medicare Part B to provide refunds for discarded amounts of the drugs. - Allowing for variation in payment rates for certain Medicare Part B drugs based on per beneficiary allowed charges. - Establishing a maximum add-on payment amount for drugs and biologicals under Medicare. - Redesigning the Medicare Part D benefit, including a manufacturer discount program and changes to reinsurance payments. - Requiring reporting on drug price increases and public disclosure of drug discounts. - Allowing certain Medicare Part D enrollees to spread out cost-sharing under certain circumstances. - Clarifying price reporting requirements for gene therapy outcomes-based agreements under Medicaid. - Providing anti-kickback statute and physician self-referral exceptions for remuneration under outcomes-based agreements. - Establishing a Chief Pharmaceutical Negotiator position at the Office of the United States Trade Representative.

Budget and Finance

https://www.congress.gov/bill/117th-congress/senate-bill/2164/all-info